DIMERIX ANNOUNCES POSITIVE TOP-LINE RESULTS IN
PHASE 2a CLINICAL STUDY OF DMX-200 IN FSGS
Highlights
• Primary and secondary endpoints met in the Phase 2a study of DMX-200 in FSGS patients
• DMX-200 was found to be generally safe and well-tolerated in FSGS patients
• 86% of patients demonstrated a reduction of proteinuria with DMX-200 versus placebo
• A 29% reduction in proteinuria was observed across all patients receiving DMX-200 compared to
placebo
• 29% of patients achieved a >40% reduction in proteinuria on DMX-200 compared to placebo
• Multiple patients from both FSGS and diabetic kidney disease studies continue on DMX-200 via
TGA Special Access Scheme
• Statistically powered Phase 2 study in diabetic kidney disease results due in 4 - 6 weeks
- Forums
- ASX - By Stock
- DXB
- Ann: Positive Top-Line Results in FSGS Phase 2a Clinical Study
Ann: Positive Top-Line Results in FSGS Phase 2a Clinical Study, page-4
-
- There are more pages in this discussion • 283 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DXB (ASX) to my watchlist
|
|||||
Last
50.5¢ |
Change
-0.045(8.18%) |
Mkt cap ! $310.8M |
Open | High | Low | Value | Volume |
56.0¢ | 58.0¢ | 47.0¢ | $5.389M | 10.26M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 207369 | 50.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
51.5¢ | 66004 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 207369 | 0.505 |
3 | 27998 | 0.500 |
4 | 125269 | 0.495 |
5 | 284816 | 0.490 |
3 | 74737 | 0.485 |
Price($) | Vol. | No. |
---|---|---|
0.515 | 66004 | 2 |
0.520 | 88413 | 3 |
0.525 | 43180 | 2 |
0.530 | 10000 | 1 |
0.535 | 7500 | 1 |
Last trade - 16.10pm 23/07/2024 (20 minute delay) ? |
Featured News
DXB (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & MD
Charles Armstrong
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online